NCT05152147 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05152147
Title	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)
Acronym	HERIZON-GEA-01
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Jazz Pharmaceuticals
Indications	gastroesophageal adenocarcinoma gastric adenocarcinoma esophagus adenocarcinoma gastroesophageal junction adenocarcinoma
Therapies	Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + Zanidatamab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Zanidatamab Cisplatin + Fluorouracil + Tislelizumab + Zanidatamab Capecitabine + Oxaliplatin + Tislelizumab + Zanidatamab
Age Groups:	adult \| senior
Covered Countries	TUR \| ROU \| POL \| NLD \| ITA \| IRL \| GRC \| GBR \| FRA \| EST \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG

No variant requirements are available.